BJDX

Bluejay Diagnostics, Inc.

$2.81

12.85%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Source: Yahoo Finance
Q-Score15/ 100
Market Cap$3.1M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.30
AI summary

Price & performance

1M-34.0%
3M-41.4%
YTD-78.9%
1Y-92.2%
52-week range—
Beta0.30
Full chart and returns against a benchmark

Q-Score

15/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk17
Performance14
Valuation31
Profitability37
Leverage18
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$6.8M
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Going-concern doubtMar 6, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

BJDXIndustryP/E—29.61P/S—3.49EV/EBITDA—18.38P/B0.333.39PEG——
Dividend yield0.00%
Every valuation metric